EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Investing in Biotech: Profits and Pitfalls

  • ID: 314486
  • Report
  • November 2005
  • Region: Global
  • 18 pages
  • Centient Consulting, Inc
1 of 4

FEATURED COMPANIES

  • Aastrom
  • Biogen Idec
  • Genentech
  • Gilead
  • Invitrogen
  • Pfizer
  • MORE
This report provides the information necessary to profit from the unfolding technological and scientific advances in biotechnology. It offers specific tips on how to get started, where to find for the information needed to identify and analyze specific investment opportunities, and how to time investments around company events and valuation inflection points.

Reasons to Purchase

- Understand the market dynamics and regulatory events driving biotechnology company valuations
- Identify the emerging technologies most likely to yield significant new drugs
- Recognize potential investment opportunities in biotechnology
- Identify 26 companies, five mutual funds and three ETFs for potential investment

Target Audience

- Fund managers, venture capitalists and individual investors seeking investments in biotech
- Analysts and journalists tracking the biotechnology market
- Others seeking to understand the driving factors and market dynamics

Report Highlights

"Investing in Biotech: Profits and Pitfalls" is an introduction to the world of investing in biotechnology. While there are many opportunities to profit from the unfolding technological and scientific advances, biotechnology is a complex, high beta industry. As such, investors should be armed with some basic knowledge and principles to maximize their returns in biotech.

One of the added benefits of investing in biotech is "to do good while doing well." You are contributing to the success of companies that are striving to extend patients' lives and find cures for deadly diseases such as cancer. New advances are made nearly daily, and by investing in biotech you are contributing to that progress while hopefully pocketing some profits.

The report provides a wealth of information on how clinical trials and other events effect company valuation, the emerging technologies shaping the future of biotech, and the performance of biotechs over pharmaceutical companies. In addition to the 26 companies covered in the report, it also discusses EFTs and mutual funds as potential investment opportunities.

"Investing in Biotech: Profits and Pitfalls" is a valuable source of information for the new investor in biotech as well as the seasoned investor seeking additional insights into the market dynamics.

Figures and Tables
Figure 1: Drug Development and Investment Life Cycle
Figure 2: Probability of Success
Figure 3: Cost per New Drug: Biotech vs. Pharma
Figure 4: Number of New Drugs: Biotech vs. Pharma
Table 1: Milestone / Inflection Point / Probability of Success

Sidebars
- Recommended Reading
- FDA Approval Criteria
- Case Study: A Critical Decision for Genentech
- Life Science Angels
- Sources of Information
- Emerging Technologies

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aastrom
  • Biogen Idec
  • Genentech
  • Gilead
  • Invitrogen
  • Pfizer
  • MORE
Introduction

Why Biotech?

What is "Biotech"?

Follow the Drug

When to Invest

Other Investment Factors

KISS: Keep it Simple to Start

Biotechnology vs. Pharmaceutical

The "Top 10" Biotechs

Conclusion
Note: Product cover images may vary from those shown
3 of 4
Aastrom
Abgenix
Advance Cell Technology
Amgen
Biogen Idec
Cambridge Antibody Technology
Corautus
Curis
Exelixis
Genentech
GenVec
Genzyme
Geron
Gilead
GlaxoSmithKline
Hybridon
ImClone
Invitrogen
Johnson & Johnson
Lexicon Genetics
New River Pharma
Pfizer
Shire Pharmaceuticals
StemCells
Vertex
ViaCell
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll